throbber
12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 1
`
` UNITED STATES PATENT AND TRADEMARK OFFICE
` BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`______________________________
`AMNEAL PHARMACEUTICALS LLC )
`and AMNEAL PHARMACEUTICALS )
`OF NEW YORK, LLC )
` )
` Petitioners )
` )
`vs. )
` )
`ALMIRALL, LLC )
` )
` Patent Owner )
`______________________________
`
` Case: IPR 2019-00207
` U.S. Patent No. 9,517,219
` Deposition of Elaine S. Gilmore, M.D.
` Washington, D.C.
` December 12, 2019 at 7:59 a.m.
`
`
`Reported by: Bonnie L. Russo
` ______________________________________________
` DIGITAL EVIDENCE GROUP
` 1730 M Street, NW, Suite 812
` Washington, D.C. 20036
` (202) 232-0646
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`1 of 192
`
`Almirall EXHIBIT 2069
`
`Amneal v. Almirall
`IPR2019-00207
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Deposition of Elaine S. Gilmore, M.D. held at:
`
`Page 2
`
` Sterne Kessler Goldstein & Fox, LLP
` 1100 New York Avenue, N.W.
` Washington, D.C.
`
`Pursuant to Notice, when were present on behalf
`of the respective parties:
`
`1
`
`2 3 4 5
`
`6
`
`7
`
`8 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`2 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 3
`
`APPEARANCES:
`
`On behalf of the Petitioners:
` ADAM C. LaROCK, ESQ.
` TYLER LIU, ESQ.
` STERNE KESSLER GOLDSTEIN & FOX
` 1100 New York Avenue, N.W.
` Washington, D.C. 20005
` 202-371-2600
` alarock@sternekessler.com
` tliu@sternekessler.com
`
`On behalf of the Patent Owner:
` R.J. SHEA, ESQ.
` FENWICK & WEST, LLP
` 902 Broadway
` Suite 14
` New York, New York 10010
` 212-921-2001
` rshea@fenwick.com
`
`1
`
`2 3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`3 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
` C O N T E N T S
`EXAMINATION OF ELAINE S. GILMORE, M.D. PAGE
`BY MR. SHEA 6
`BY MR. LaROCK 185
`
`Page 4
`
` PREVIOUSLY MARKED EXHIBITS
` PAGE
`Exhibit 1001 United States 11
` Patent 9,517,219 B2
`Exhibit 1004 International Publication 6
` Number WO 2009/061298 A1
`Exhibit 1018 Declaration of Elaine S. 89
` Gilmore, M.D., Ph.D.
`Exhibit 1019 Curriculum Vitae of 15
` Elaine S. Gilmore,
` M.D., Ph.D.
`Exhibit 1044 Second Declaration of 78
` Elaine S. Gilmore,
` M.D., Ph.D.
`Exhibit 1048 Article entitled 160
` "The Efficacy and
` Tolerability of Dapsone
` 5% Gel in Female vs Male
` Patients With Facial Acne
` Vulgaris: Gender as a
` Clinically Relevant
` Outcome Variable"
`
`1
`2
`3
`4
`
`5 6 7 8
`
`9
`10
`
`11
`12
`13
`
`14
`15
`
`16
`17
`
`18
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`4 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 5
`
`EXHIBITS (CONTINUED):
` PAGE
`Exhibit 1077 Third Declaration of 186
` Elaine S. Gilmore,
` M.D., Ph.D.
`Exhibit 2001 International Publication 121
` Number WO 2009/108147 A1
`Exhibit 2024 Review Article entitled 54
` "Current topical and
` systemic approaches to
` treatment of rosacea"
`Exhibit 2055 Declaration of 14
` Leon H. Kircik, M.D.
` in Support of Patent
` Owner's Response to
` Petition for Inter Partes
` Review
`
`(Exhibits included with transcript.)
`
`1
`2
`
`3
`
`4
`5
`6
`
`7
`
`8
`9
`
`10
`
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`5 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
` P R O C E E D I N G S
`
`Page 6
`
` ELAINE S. GILMORE, M.D.,
`was called for examination by counsel and,
`after having been duly sworn by the Notary, was
`examined and testified as follows:
` EXAMINATION BY COUNSEL FOR PATENT OWNER
` BY MR. SHEA:
` Q. Good morning.
` Thanks for being here. We'll try to
`make this as quick and painless as possible.
` So I understand that you've done a
`couple depositions before, even related to the
`dapsone formulations and stuff; is that right?
` A. Correct.
` Q. So you just understand the basic
`gist of the depositions and how they go?
` A. Yes.
` Q. Okay. So just a few housekeeping
`things.
` I'm going to hand you your
`declaration. It's Exhibit 1044.
`
`1
`
`2 3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`6 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 7
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` And that's your declaration that you
`signed I believe on October 31st, 2019, right?
` A. Yes.
` Q. And have you had a chance to review
`that since then?
` A. Yes.
` Q. Do you have any edits or corrections
`or comments that you would like to change about
`the declaration?
` A. Yes. I have several reference
`errata to report.
` Q. Okay. And hold on.
` MR. LaROCK: I'll just read them.
` BY MR. SHEA:
` Q. And what would those be?
` A. Both pertaining to the reply
`declaration as well as my third declaration,
`which you haven't given me yet.
` On my reply declaration on page 11,
`paragraph --
` Q. I'm sorry. So we're on Exhibit
`1044, right?
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`7 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 8
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` A. Yes.
` Q. And that's your second declaration?
` A. Yeah. I call it the reply
`declaration, yes.
` Q. Well, on the cover page, it just --
`just so we're clear --
` A. Second declaration.
` Q. Yeah. Second declaration.
` A. Yes.
` Q. Okay. So this is the one that
`we're -- you have comments or corrections on?
` A. Yes.
` Q. Okay. So when you're ready, do you
`just want to direct me to the paragraph that
`you're...
` A. On Page 11, the third bullet point
`should say "Exhibit 2019."
` Q. So instead of Exhibit 2031, 2039?
` A. No. The third bullet point.
` Q. On that page.
` A. On that page.
` Q. So instead of Exhibit 2009, Exhibit
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`8 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 9
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`2029?
` A. 2019.
` Q. 19. Okay.
` A. And on the last line of that same
`bullet point, the same reference, Exhibit 2019.
` Q. Okay.
` A. And those are all the changes I have
`for the second declaration.
` Q. Okay. Let's just stop there. And
`then, when we get to the exhibit that you have
`another correction for -- do you have the
`exhibit numbers that you have corrections for?
` A. Yes. So in different paragraphs.
`So we have "Exhibit 1065," which needs to be
`deleted from two of the sentences.
` Q. I'm sorry. So let me just clarify.
` You want to make corrections to
`Exhibit 1065?
` A. I want to change the number of the
`exhibit in the sentence.
` Q. In Exhibit 1044 or Exhibit 1065
`that --
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`9 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 10
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` A. I don't know what the exhibit is
`going to be named, but it's the third
`declaration. Not this one. The third
`declaration.
` MR. LaROCK: There was a
`supplemental declaration having to do with
`authenticating certain evidence that was served
`on counsel.
` MR. SHEA: Okay. Let's get to that
`one when we get there.
` THE WITNESS: Okay.
` BY MR. SHEA:
` Q. I was confused as to what the edits
`were, if it was in this declaration or if it
`was in a different declaration.
` A. We've taken care of edits for this
`declaration.
` Q. Okay. And then what other exhibits
`would you like to make corrections to?
` A. So nothing further in the second
`declaration.
` Q. Yep.
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`10 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 11
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` A. In the third declaration, it's just
`citations to different references.
` Q. Sure.
` And then are there any other
`exhibits that you want to make changes to?
` A. It pertains to the same exhibit
`cited in two different paragraphs in that other
`-- it's -- it was an omission.
` Q. Okay. All right. Sounds good. So
`we'll get to that one when we're -- when we do
`it.
` So as far as Exhibit 1044, your
`second declaration, are there any other
`corrections or comments that you have on that?
` A. No.
` Q. Okay. I'm going to hand you now
`Exhibit 101 [sic], which is U.S. Patent
`9,517,219.
` I'll just refer to that as the '219
`patent.
` You understand that?
` A. Yes.
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`11 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 12
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` Q. And you understand that this is the
`patent at issue for this IPR?
` MR. LaROCK: This is Exhibit 1001?
` MR. SHEA: Yes.
` MR. LaROCK: Okay. I thought you
`said 101. Sorry.
` THE WITNESS: Yes.
` BY MR. SHEA:
` Q. So you understand that this is the
`patent at issue today?
` A. Yes.
` Q. And just more housekeeping, just
`terms.
` When I say a POSA, P-O-S-A, you
`understand that to mean a person of ordinary
`skill in the art?
` A. Yes.
` Q. And if we just turn to the claims of
`the patent, which is on the last page there,
`Column 16, you see in Claim 2 it says
`"diethylene glycol monoethyl"?
` If we refer to that as DGME, would
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`12 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 13
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`you understand that?
` A. I can understand that would be an
`abbreviation.
` Q. Sure.
` A. I'm not a formulator of medications.
` Q. Understood.
` Just for shorthand, if we refer to
`it as DGME, you'll understand it references
`that term?
` A. Understood.
` Q. And likewise, in Claim 3, it says
`"polymeric viscosity builder."
` If we refer to that as PVB for
`shorthand, is that okay?
` A. I understand.
` Q. And then the last one in Claim 6, it
`says "acrylamide\sodium acryloyldimethyl
`taurate copolymer."
` If we just refer to that as ASA for
`shorthand, is that okay?
` A. That's okay.
` Q. Okay. And then this is also just --
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`13 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 14
`I'm going to hand you Dr. Kircik's declaration,
`which is Exhibit 2055.
` And that -- this is just for your
`reference, just in case you need to refer to it
`throughout the deposition or anything like
`that.
` So in the deposition, I'm going to
`ask you questions, and you will understand that
`the court reporter will record your answer.
` Do you understand that?
` A. Yes.
` Q. And you understand that a verbal
`response is needed, you know, head nods or
`"uh-huh" won't work?
` A. I understand.
` Q. And because we have a court reporter
`here, if you just let me finish my question,
`and likewise I'll let you finish your answer,
`and that will keep the record clean.
` Will that work too?
` A. Yes.
` Q. Okay. And if you find one of my
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`14 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 15
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`questions ambiguous or difficult, if you could
`just state that while -- in your response. And
`then I can clarify.
` If you don't state anything, I'll
`just assume that you understood the question.
` A. Okay.
` Q. And you also understand that you're
`under oath today?
` A. I understand.
` Q. Okay. And is there any reason why
`you can't provide truthful or accurate
`testimony today?
` A. No.
` Q. Okay. Dr. Gilmore, I just want to
`talk to you a little bit about your CV, which
`I'm handing to you. It's Exhibit 1019.
` That's your CV, correct?
` A. Yes.
` Q. Do you have any updates, any new
`papers, anything that you want to add to that?
` A. I have new international
`presentation from September of this year that's
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`15 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 16
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`not included.
` Q. Did that presentation concern
`dapsone or dapsone formulations?
` A. No.
` Q. Was it concerning dermatology?
` A. Yes.
` Q. And just generally, what was it
`about?
` A. Allergic contact dermatitis related
`to particular topical therapies for cutaneous
`lymphoma.
` Q. Okay. So would acne or rosacea have
`been involved in that at all?
` A. No.
` Q. Now, in your declaration on
`Paragraph 20 -- I'll give you a minute to the
`get there -- you just describe a POSA as
`possessing an M.D. with a board certification
`in dermatology with at least two years of
`experience in dermatology or otherwise treating
`skin conditions.
` Is that accurate?
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`16 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 17
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` A. I don't see that in Paragraph 20.
` MR. LaROCK: Where are we?
` BY MR. SHEA:
` Q. On Paragraph 20 of your first
`declaration. I'm sorry. Here I'll give that
`to you. I'm sorry. I'm sorry for -- I don't
`mean to bombard you with a bunch of exhibits
`here.
` Paragraph 20.
` A. Could you repeat your question,
`please.
` Q. Yeah.
` Does Paragraph 20 accurately
`describe what you consider a POSA?
` A. It accurately describes my
`impression of a clinical POSA.
` Q. And when I say "priority date" or
`"at the time of the invention," you understand
`that that would be November 20th, 2012, the
`priority date of the patent, '219 patent?
` A. I understand that.
` Q. You were a resident from 2004 to
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`17 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 18
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`2007; is that right?
` A. Correct.
` Q. And then you were just a research
`fellow from 2006 to 2008?
` A. I was also practicing dermatology.
` Q. Sure.
` So from your research fellow or your
`residency, how many years would you consider
`yourself a POSA until the time of the
`invention?
` MR. LaROCK: Objection. Vague.
` THE WITNESS: So as I indicated in
`the first deposition, I said it is also
`possible that an MD without a certification in
`dermatology, i.e., primary care physician or a
`pediatrician, may qualify as a clinical POSA,
`assuming that they have more than two years of
`knowledge and experience treating skin
`conditions.
` So I graduated from medical school
`in 2003. And then was involved in clinical
`medicine from that point forward.
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`18 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 19
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` Q. So just focusing on your time from
`when you were a resident to the time of the
`invention, how many papers or publications did
`you publish?
` I will direct you to Page 2 of your
`CV there. I believe it starts on No. 11 there.
` Would that be within -- before the
`time of the invention?
` A. Yes.
` Q. And then it goes down to No. 17,
`which is Huang.
` Do you see that one on page 3?
` A. I see the reference.
` Q. And would that be your first paper
`after graduating med school?
` A. Yes.
` Q. So from those two, 11 to 17, you
`published seven papers between residency and
`the time of the invention?
` A. Yes.
` Q. Were any of those papers related to
`dapsone?
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`19 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 20
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` A. No.
` Q. Were any of them related to topical
`formulations?
` A. I don't recall the full contents of
`what was included in Reference No. 15. It was
`a book chapter. And I have not reviewed that
`in many years, so I'm not sure what's included
`in there, whether there are topical treatments
`or not.
` Q. And other than 15, were any of them
`concerning topical formulations?
` A. No.
` Q. Were any related to acne or rosacea?
` A. No.
` Q. And, Dr. Gilmore, before the
`priority date -- and I'll just direct you to
`Kircik's declaration at Paragraph 5, which I
`believe is Exhibit 2055.
` Before the priority date, were you
`invited to any present -- professional
`presentations or professional talks in the
`industry?
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`20 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 21
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` A. What do you mean by "invited to any
`professional talks"?
` Q. Did academia, did the private
`sector -- was anybody hired -- did anybody hire
`you to give professional talks?
` And I would direct you to Page 3 of
`your CV, where you list out your presentations
`and national and international presentations.
` MR. LaROCK: Objection. Vague.
` THE WITNESS: So typically, with
`scientific research publications, you're not
`hired to give them. It's more likely you are
`invited to speak at different meetings. So
`being hired by someone to do something is not
`really an honor.
` BY MR. SHEA:
` Q. Sure.
` And what I'm just getting at, if you
`look at Page 3 of your CV, if you were hired,
`invited to give any presentations before the
`date of the invention.
` A. Well, I don't know -- it looks like
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`21 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 22
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`the date of the invention you have as November
`20th, 2012. I'm not sure when I was invited to
`present at Nephrology Grand Rounds, also
`November 2012.
` Q. Okay. So -- and just -- sorry.
` I'm -- what one are you referencing
`there?
` A. Management of Uremic Pruritis,
`University of Rochester, Nephrology Grand
`Rounds.
` Q. So other than that --
` A. That's not something you're paid to
`do.
` Q. Sure.
` And other than that, were there any
`other presentations that you were invited,
`hired to give before the date of the invention?
` MR. LaROCK: Limited to her CV?
` MR. SHEA: Limited to her
`experience.
` THE WITNESS: I don't see it listed
`here. I can remember giving presentations at
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`22 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 23
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`the American Academy of Dermatology when I was
`a resident. I don't have it here.
` BY MR. SHEA:
` Q. You said the management of uremic
`pruritis.
` Does that have to do with dapsone
`formulations?
` A. No.
` Q. Also, Dr. Gilmore, prior to the date
`of the invention, were you on the editorial
`board of any journals?
` A. No.
` Q. Were you a consultant to the private
`industry at all before the date of the
`invention?
` A. No.
` Q. Were you invited to any symposiums
`or industry meetings before the date of the
`invention?
` A. No.
` Q. Before the priority date, were you
`involved in clinical studies at all?
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`23 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 24
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` A. Yes.
` Q. What clinical studies would those
`be?
` A. They were ongoing clinical trials in
`the department when I was a resident at Yale.
`And I've been involved in clinical trials
`regarding cutaneous lymphoma when I was at the
`University of Rochester and since.
` Q. You said you were involved as a
`resident.
` For those clinical trials, what was
`the topic about there?
` A. I don't remember specifically.
` Q. But it wasn't about dapsone
`formulations?
` A. No.
` Q. Was it about topical formulations?
` A. I don't recall.
` Q. And your role in those clinical
`trials, what would that be?
` A. Mainly as an observer.
` Q. So you didn't influence or direct
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`24 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 25
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`the clinical design at all?
` A. No.
` Q. You didn't help design it?
` A. No.
` Q. And you mentioned another clinical
`trial after your residency, correct?
` A. Yes.
` Q. Was that clinical trial about
`dapsone?
` A. No.
` Q. Was that clinical trial about
`topical formulations?
` A. Yes.
` Q. And was it -- was that clinical
`trial about acne or rosacea?
` A. No.
` Q. And again, what was your role for
`that clinical trial?
` A. Coinvestigator.
` Q. And as a coinvestigator, what would
`your duties be?
` A. Evaluate patients responses, design,
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`25 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 26
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`patch testing, assessments.
` Q. And what year was that?
` A. It's current.
` Q. Ongoing -- so --
` A. Ongoing.
` Q. So it started before?
` A. There were other trials that have
`started and ended basically since 2008.
` Q. Okay. So I'm not talking about the
`clinical trial that you're currently in.
` You said that -- I asked, before the
`priority date, if you were involved in any
`clinical trials, right?
` You understood that?
` A. Yes.
` Q. And you said that there was the one
`as a resident, and then you said there was
`another one that you were -- while you were at
`New Haven; is that right?
` MR. LaROCK: Objection to the extent
`it mischaracterizes her testimony.
` THE WITNESS: That's not what I
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`26 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 27
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`said.
` BY MR. SHEA:
` Q. Sure.
` I'm not trying to mischaracterize it
`at all. And I apologize. I'm just trying --
`I'm a little confused, so I'm just trying to
`understand.
` What clinical trials did you do
`before the priority date?
` A. There were clinical trials that
`started in 2008 when I was at the University of
`Rochester, in which I was a coinvestigator,
`that have run their course and completed.
` We always have ongoing clinical
`trials, of which I am part.
` Q. Sure.
` So the clinical trial in 2008, when
`did that end?
` A. I don't remember the specifics.
` Q. And that clinical trial in 2008, you
`said you were a coinvestigator.
` So what would that role be for that
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`27 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 28
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`2008 clinical trial?
` A. Evaluating patient responses to
`treatment, physical exams. Another clinical
`trial evaluating a microscopy evaluation of
`nevi in the skin.
` Q. Sure.
` A. I've been involved in many clinical
`trials.
` Q. And I understand. I'm just trying
`to focus on the 2008 one.
` So for that 2008 clinical trial, was
`that involving topical formulations?
` A. I don't remember specifically. I
`think that might have been an infusion. But
`there have been many clinical trials that I
`have been involved in.
` Q. And --
` A. Some are topical; some are oral;
`some are infusional; others were
`microscopy-directed.
` Q. And for that 2008 clinical trial,
`that didn't involve dapsone?
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`28 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 29
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` A. Yes. That didn't involve dapsone.
` Q. And that clinical trial -- 2008
`clinical trial was not about acne or rosacea?
` A. Correct.
` Q. Okay. And so before the priority
`date, you were involved in two clinical trials,
`one while you were a resident and then one in
`2008; is that correct?
` MR. LaROCK: Objection to the extent
`it mischaracterizes her testimony.
` THE WITNESS: I don't know how many
`there were. I think there were more than two.
` BY MR. SHEA:
` Q. But you can't recall those right
`now?
` A. No. I didn't comment on that or
`review that information.
` Q. Dr. Gilmore, you're testifying on
`behalf of Amneal as a clinical expert; is that
`right?
` A. Yes.
` Q. And a clinical expert as opposed to
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`29 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 30
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`a formulation expert?
` You understand that difference and
`--
` A. Yes.
` Q. -- make the distinction?
` So what, in your view, is the
`difference between a clinical expert and a
`formulation expert?
` MR. LaROCK: Objection. Outside the
`scope of her declaration.
` THE WITNESS: I can only comment on
`a clinical expert's perspective, given that
`that's my role. And it is to comment on
`treatment of patients with acne.
` BY MR. SHEA:
` Q. So as a clinical expert, you
`wouldn't be able to testify about formulation
`designs?
` A. I would not testify about
`formulation designs.
` Q. You wouldn't -- it wouldn't be
`within your scope of expertise to know how
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`30 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 31
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`excipients and active ingredients interact?
` MR. LaROCK: Objection. Vague.
` THE WITNESS: Those are not things
`that I have considered.
` BY MR. SHEA:
` Q. And it also wouldn't be within your
`scope of expertise to understand how different
`active ingredients interact with each other --
`with another active ingredient?
` MR. LaROCK: Objection. Vague.
` THE WITNESS: Those aren't things
`that I would be talking about.
` BY MR. SHEA:
` Q. So just hypothetically, if an active
`ingredient concentration was increased, it
`would be outside your scope of expertise to
`know how that influences the final product, the
`final -- the viscosity, the grittiness?
` MR. LaROCK: Objection. Vague.
`Compound. And object to the extent it
`mischaracterizes her declaration.
` THE WITNESS: Can you restate your
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`31 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 32
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`question.
` BY MR. SHEA:
` Q. Yes.
` So it would be outside your
`expertise, if an active ingredient
`concentration was increased, to understand how
`that would affect the product's -- the final
`product's viscosity?
` MR. LaROCK: Objection. Outside the
`scope of her declaration.
` THE WITNESS: I'm not prepared to
`talk about viscosity of topical formulations.
`I'm here to discuss the clinical use of
`medications in treating acne.
` BY MR. SHEA:
` Q. Sure.
` I mean the viscosity for clinical
`use.
` If you're prescribing a medication,
`you're concerned about the viscosity, correct?
` MR. LaROCK: Objection. Outside the
`scope.
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2019
`
`202-232-0646
`
`32 of 192
`
`

`

`12/12/2019
`
`Amneal Pharmaceuticals, et al., v. Almirall, S.A.
`
`Elaine Gilmore, M.D.
`
`Page 33
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` THE WITNESS: In prescribing
`medications, I'm not usually talking about or
`using the word "viscosity" with my patients.
` BY MR. SHEA:
` Q. What word would you use?
` A. We talk about efficacy. We talk
`about cost. We talk about application.
` Q. Doctor, I just want to talk to you
`about your prescribing habits and that
`procedure.
` So before the time of the invention,
`you prescribed Aczone; is that correct?
` A. Yes.
` Q. Did you prescribe Aczone for acne?
` A. Yes.
` Q. And again, before the time of the
`invention, did you prescribe it for rosacea?
` A. I don't recall using it for rosacea.
` Q. And be

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket